RxDoctor Payments Data

Lauren Blitzer, NP

Nurse Practitioner · Phoenix, AZNPI 1902409824

Payments from drug & device makers

$3,519in general payments, 2019–2025

Across 154 payments — averaging $22.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$717
  • AstraZeneca$586
  • Lilly USA, LLC$378
  • Astellas Pharma US Inc$216
  • Janssen Scientific Affairs, LLC$181
  • Pfizer$174
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$3,39496%
  • Education$1254%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,519 in reported general payments places this provider in the 90th percentile of 1,719 nurse practitioner providers in Arizona.

See all nurse practitioner providers in Arizona

Medicare billing

Part B allowed, 2024
$83,257
Medicare patients
467
Services billed
1,088

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$85,184
EliquisApixaban53$72,979
JardianceEmpagliflozin35$54,743
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$26,228
ProliaDenosumab12$20,781
FarxigaDapagliflozin Propanediol13$19,231
XareltoRivaroxaban19$18,759
Tresiba Flextouch U-200Insulin Degludec11$14,047
Levothyroxine Sodium376$4,557
Gabapentin134$3,152
SynthroidLevothyroxine Sodium28$3,019
Rosuvastatin Calcium183$2,186
Atorvastatin Calcium327$2,179
Pantoprazole Sodium157$2,063
Omeprazole124$2,046

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$130$85,18454 claims
PfizerEliquis$174$72,97953 claims
Boehringer IngelheimJardiance$42$54,74335 claims
GSKTrelegy Ellipta$170$26,22816 claims
AmgenProlia$99$20,78112 claims
AstraZenecaFarxiga$586$19,23113 claims
Johnson & JohnsonXarelto$125$18,75919 claims
AbbVieSynthroid$717$3,01928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,719 nurse practitioner providers in Arizona.

Other nurse practitioner in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →